Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 192

Sort by

Sort Order Select

Journal Articles

Cost-Effectiveness of Venetoclax and Rituximab Combination Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in Argentina

Jorge Federico Elgart, Economist, Mariana Glancszpigel, Economist, Diego Kanevsky, Biochemist, Maria Godar, BS, Valeria Touliet, Natalia Albaytero, Dentist

Blood (2019) 134 (Supplement_1): 2139.

https://doi.org/10.1182/blood-2019-121490

Published: 2019

Journal Articles

Cost-Effectiveness Model of Recombinant FVIII Versus Emicizumab Treatment of Patients With Severe Hemophilia A Without Inhibitors

Shawn X. Sun, Yanyu Wu, Michael McDermott, Marjolijn van Keep

Blood (2019) 134 (Supplement_1): 2102.

https://doi.org/10.1182/blood-2019-124421

Published: 2019

Journal Articles

Cost-Effectiveness of Avatrombopag for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease

Lee F. Allen, MD PhD, Kavita Aggarwal, PharmD, Michael Vredenburg, PhD, Christine Barnett, PhD, Deirdre Mladsi, BA, Ray Kim, MD

Blood (2019) 134 (Supplement_1): 3454.

https://doi.org/10.1182/blood-2019-131822

Published: 2019

Journal Articles

Estimating the Relative Treatment Effect and Corresponding Cost-Effectiveness Estimates of Inotuzumab Ozogamicin Vs. Blinatumomab for Adults with Philadelphia Chromosome-Negative (Ph-) Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukaemia (B-ALL) in the United Kingdom (UK)

Simone Critchlow, Miranda Cooper, Ilse van Oostrum, Verna L Welch, PhD MPH, T. Alexander Russell-Smith

Blood (2019) 134 (Supplement_1): 3427.

https://doi.org/10.1182/blood-2019-123454

Published: 2019

Journal Articles

Superiority of IFN Versus HU Using a Novel Biomarker-Based Tool for Assessment of Disease Burden in MPNs

Vibe Skov, PhD, Marc JB Dam, Rasmus K Pedersen, Morten Andersen, PhD, Trine Alma Knudsen, MD, Zamra Sajid, Lasse Kjær, PhD, Christina Ellervik, MD PhD, Hans Hasselbalch, MD, Johnny T Ottesen, PhD

Blood (2019) 134 (Supplement_1): 2972.

https://doi.org/10.1182/blood-2019-126819

Published: 2019

Journal Articles

Cost Effectiveness of Novel Agents in the Treatment of Multiple Myeloma: A Systematic Review

Sarah Perry, MD MSc, Sylvia McCulloch, MD MSc

Blood (2019) 134 (Supplement_1): 4738.

https://doi.org/10.1182/blood-2019-125454

Published: 2019

Journal Articles

Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab in First-Line Chronic Lymphocytic Leukemia in the United States

Matthew S. Davids, MD, Anuja Chatterjee, MSc, Arliene Ravelo, MPH, Sheila Shapouri, PharmD, MS, Beenish S Manzoor, PhD, Kavita Sail, PhD, Gijs Van de Wetering, PhD, Michael Hallek

Blood (2019) 134 (Supplement_1): 4741.

https://doi.org/10.1182/blood-2019-123706

Published: 2019

Journal Articles

Levofloxacin Prophylaxis Is Effective and Cost-Effective in Pediatric Patients with Acute Myeloid Leukemia

Meghan McCormick, MD, Erika Friehling, MD, Ram Kalpatthi, MD, Ken Smith, MD MS

Blood (2019) 134 (Supplement_1): 335.

https://doi.org/10.1182/blood-2019-122071

Published: 2019

Journal Articles

The Validation of the BCR/ABL1 -like Predictor across Laboratories Shows Reproducibility of Results

Sabina Chiaretti, MD PhD, Taherinasab Akram, Canichella Martina, Monica Messina, Alfonso Piciocchi, Cyril Šálek, MD PhD, Katerina Machova, Katerina Blagoevova, Jordi Ribera, PhD, Josep-Maria Ribera, MD PhD, Manja Meggendorfer, PhD, Claudia Haferlach, MD, Anna Guarini, PhD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 5211.

https://doi.org/10.1182/blood-2019-122116

Published: 2019

Journal Articles

Refining Blood Products Utilization: Every One (unit) Matters

Khaled Deeb, PhD MBA, MD, Chen Zhang, MD, Stanislav Ivanov, MD MPH, Eric Szu, MD, Louis Lit, MD

Blood (2019) 134 (Supplement_1): 4985.

https://doi.org/10.1182/blood-2019-121339

Published: 2019

Journal Articles

Comparison of Three Assays for Identification of IDH Mutations in AML

Sara Ribeiro, BSc, Dorte Wren, PhDFRCPath, Lisa Thompson, PhD MSc, FIBMS, Michael Hubank, PhD, David Taussig, PhD MRCP, FRCPath

Blood (2019) 134 (Supplement_1): 5195.

https://doi.org/10.1182/blood-2019-126494

Published: 2019

Journal Articles

Bolus: Targeted Specialist Haematology Education

Sonia Thomas, Sarah Jordan, RN, MSc, Gavin Cooper, RN, BSc, Stephen D Rowley, RN, RSCN, BSc (Hons), MSc, Simon Clare, MSc

Blood (2019) 134 (Supplement_1): 5863.

https://doi.org/10.1182/blood-2019-128397

Published: 2019

Journal Articles

Cost Effective Cardio Protective Intervention in Haploidentical Hematopoietic Stem Cell Transplantation in Children - a Study from a Tertiary Care Centre in India

Revathi Raj, Ramya Uppuluri, MD, Venkateswaran Vellaichamy, MD, Nikila Ravichandran, MD, Kesavan Melarkode Ramanan, MD

Blood (2019) 134 (Supplement_1): 5866.

https://doi.org/10.1182/blood-2019-131539

Published: 2019

Journal Articles

Prevention of transfusion-transmitted infections

Michael P. Busch, Evan M. Bloch, Steven Kleinman

Blood (2019) 133 (17): 1854–1864.

https://doi.org/10.1182/blood-2018-11-833996

Published: 2019

Journal Articles

Cost Effectiveness of Rituximab As Adjunctive Therapy in Reducing Apheresis Procedures and Hospital Length of Stay in Relapsed Thrombotic Thrombocytopenic Purpura

George Goshua, MD, Amit Gokhale, MD, Jeanne E. Hendrickson, MD, Christopher Tormey, MD, Alfred Ian Lee, MD PhD

Blood (2018) 132 (Supplement 1): 3814.

https://doi.org/10.1182/blood-2018-99-113621

Published: 2018

Journal Articles

Evaluation of Recombinant Factor VIIa Utilization and Development of a Cost-Effective Dose Minimization Protocol in Adult Cardiac Surgery Patients at an Academic Medical Center

Kathryn Dane, PharmD, John Lindsley, PharmD, Satish Shanbhag, MD, Michael B. Streiff, MD, Glenn Whitman, MD, J H Abernathy, III, MD MPH, Jessica Crow, PharmD

Blood (2018) 132 (Supplement 1): 5039.

https://doi.org/10.1182/blood-2018-99-119908

Published: 2018

Journal Articles

Cost-Effective Use of White Blood Cell Growth Factors in the Veterans Administration

Kevin Knopf, MD, William Hrureshky, Bryan Love, Leann Norris, Charles L. Bennett, MD PhD

Blood (2018) 132 (Supplement 1): 4761.

https://doi.org/10.1182/blood-2018-99-119724

Published: 2018

Journal Articles

Cost-Effectiveness and Cost-Utility Analysis of ABVD Versus Beacopp in the Treatment of Advanced-Stage Hodgkin Lymphoma

Abi Vijenthira, MD, Kelvin Chan, MD PhD, Matthew Cheung, MD MS, FRCP, Anca Prica, MD

Blood (2018) 132 (Supplement 1): 2248.

https://doi.org/10.1182/blood-2018-99-113103

Published: 2018

Journal Articles

Bilateral, Simultaneous Total Knee Replacement (TKR) Surgery for Hemophilia a with Eloctate (Extended Half Life Product)—A Feasible and Cost Effective Approach

Shashikant Apte, MD FRCPA, Rajesh Phatale, MD, Aditi Joshi, BAMS, Kannan Subramanian, MD DM, MBBS

Blood (2018) 132 (Supplement 1): 4684.

https://doi.org/10.1182/blood-2018-99-116160

Published: 2018

Journal Articles

Cost-Effectiveness of Axicabtagene Ciloleucel for Relapsed or Refractory Dffuse Large B-Cell Lymphoma in Italy

Monia Marchetti, Elisa Martelli, Pier Luigi Zinzani, MD

Blood (2018) 132 (Supplement 1): 4779.

https://doi.org/10.1182/blood-2018-99-113838

Published: 2018

NARROW

Cost-Effectiveness of Venetoclax and Rituximab Combination Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in Argentina

Cost-Effectiveness Model of Recombinant FVIII Versus Emicizumab Treatment of Patients With Severe Hemophilia A Without Inhibitors

Cost-Effectiveness of Avatrombopag for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease

Estimating the Relative Treatment Effect and Corresponding Cost-Effectiveness Estimates of Inotuzumab Ozogamicin Vs. Blinatumomab for Adults with Philadelphia Chromosome-Negative (Ph-) Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukaemia (B-ALL) in the United Kingdom (UK)

Superiority of IFN Versus HU Using a Novel Biomarker-Based Tool for Assessment of Disease Burden in MPNs

Cost Effectiveness of Novel Agents in the Treatment of Multiple Myeloma: A Systematic Review

Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab in First-Line Chronic Lymphocytic Leukemia in the United States

Levofloxacin Prophylaxis Is Effective and Cost-Effective in Pediatric Patients with Acute Myeloid Leukemia

The Validation of the BCR/ABL1 -like Predictor across Laboratories Shows Reproducibility of Results

Refining Blood Products Utilization: Every One (unit) Matters

Comparison of Three Assays for Identification of IDH Mutations in AML

Bolus: Targeted Specialist Haematology Education

Cost Effective Cardio Protective Intervention in Haploidentical Hematopoietic Stem Cell Transplantation in Children - a Study from a Tertiary Care Centre in India

Prevention of transfusion-transmitted infections

Cost Effectiveness of Rituximab As Adjunctive Therapy in Reducing Apheresis Procedures and Hospital Length of Stay in Relapsed Thrombotic Thrombocytopenic Purpura

Evaluation of Recombinant Factor VIIa Utilization and Development of a Cost-Effective Dose Minimization Protocol in Adult Cardiac Surgery Patients at an Academic Medical Center

Cost-Effective Use of White Blood Cell Growth Factors in the Veterans Administration

Cost-Effectiveness and Cost-Utility Analysis of ABVD Versus Beacopp in the Treatment of Advanced-Stage Hodgkin Lymphoma

Bilateral, Simultaneous Total Knee Replacement (TKR) Surgery for Hemophilia a with Eloctate (Extended Half Life Product)—A Feasible and Cost Effective Approach

Cost-Effectiveness of Axicabtagene Ciloleucel for Relapsed or Refractory Dffuse Large B-Cell Lymphoma in Italy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only